Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
LUVOX CR is an extended-release oral capsule formulation of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) approved in 2008. The mechanism of action involves inhibition of serotonin reuptake at the presynaptic membrane, increasing synaptic serotonin availability. LUVOX CR is indicated for obsessive-compulsive disorder and other psychiatric conditions where SSRIs are therapeutically appropriate.
Product is in mature/declining phase with moderate competitive pressure (30/100), indicating smaller brand teams focused on maintenance and line extension rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
LUVOX CR roles offer stability in a mature psychiatric franchise but limited growth trajectory. Career progression will depend on cross-product portfolio responsibility and shift toward adjacent therapeutic areas within Jazz Pharmaceuticals' neuroscience pipeline.
Worked on LUVOX CR at Jazz Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.